University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Items where Author is "Kaye, S"

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 8.

Article

Ang, JE, Pal, A, Asad, YJ, Henley, AT, Valenti, M, Box, G, de haven Brandon, A, Revell, Victoria, Skene, Debra, Venturi, M, Rueger, R, Meresse, V, Eccles, SA, de Bono, JS, Kaye, SB, Workman, P, Banerji, U and Raynaud, FI (2017) Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655: pharmacodynamic and predictive potential in metastatic melanoma. Molecular Cancer Therapeutics.

McNeish, IA, Ledermann, JA, Webber, L, James, L, Kaye, SB, Hall, M, Hall, G, Clamp, A, Earl, H, Banerjee, Saikat, Kristeleit, R, Raja, F, Feeney, A, Lawrence, C, Dawson-Athey, L, Persic, M and Khan, I (2014) A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer Annals of Oncology, 25 (10). pp. 1988-1995.

Yap, TA, Vidal, L, Pandha, H, Spicer, J, Digue, L, Coffey, M, Thompson, B, Kaye, SB, Harrington, KJ and De-Bono, JS (2006) A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer EJC SUPPLEMENTS, 4 (12). p. 108.

Conference or Workshop Item

Ang, JE, Pandher, R, Asad, Y, Skene, DJ, Workman, P, Eccles, S, De Bono, J, Kaye, S, Banerji, U, Davies, S and Raynaud, FI (2014) Plasma metabolomic signature of novel signal transduction inhibitors from preclinical identification to clinical validation In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2014-11-18 - 2014-11-21, European Org Res & Treatment Canc, Barcelona, SPAIN.

McNeish, IA, Ledermann, JA, Webber, LC, James, LE, Kaye, SB, Rustin, GJS, Hall, G, Clamp, A, Earl, HM, Banerjee, SN, Kristeleit, RS, Raja, F, Feeney, A, Lawrence, C, Dawson-Athey, L, Persic, M and Khan, I (2013) A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC) In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 2013-05-31 - 2013-06-04, Chicago, IL.

Vidal, L, Pandha, H, Spicer, J, Harrington, KJ, Allen, S, Leader, D, Coffey, M, Thompson, B, Kaye, S and De-Bono, J (2006) A phase I study of reolysin given intravenously to patients with advanced malignancies. In: 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, 2006-06-02 - 2006-06-06, Atlanta, GA.

Vidal, L, Twigger, K, White, C, Coffey, M, Thompson, B, De-Bono, J, Pandha, HS, Melcher, A, Kaye, S and Harrington, KJ (2005) Reovirus enhances radiation cytotoxicity in vitro and in vivo. In: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2005-11-14 - 2005-11-18, Philadelphia, PA.

Vidal, L, Pandha, H, Harrington, K, Fong, P, Shaw, H, Barrett, M, Leader, D, White, C, Twigger, K, Coffey, M, Thompson, B, Kaye, S and De-Bono, J (2005) A phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies. In: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2005-11-14 - 2005-11-18, Philadelphia, PA.

This list was generated on Sun Nov 19 10:32:28 2017 UTC.

Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800